Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).
Paying user area
Try for free
Cytokinetics Inc. pages available for free this week:
- Income Statement
- Cash Flow Statement
- Analysis of Short-term (Operating) Activity Ratios
- Analysis of Long-term (Investment) Activity Ratios
- Operating Profit Margin since 2005
- Total Asset Turnover since 2005
- Price to Operating Profit (P/OP) since 2005
- Price to Book Value (P/BV) since 2005
- Analysis of Revenues
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Cytokinetics Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Current Valuation Ratios
Cytokinetics Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | Pharmaceuticals, Biotechnology & Life Sciences | Health Care | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data | ||||||||||||||||||
Current share price (P) | ||||||||||||||||||
No. shares of common stock outstanding | ||||||||||||||||||
Earnings per share (EPS) | ||||||||||||||||||
Operating profit per share | ||||||||||||||||||
Sales per share | ||||||||||||||||||
Book value per share (BVPS) | ||||||||||||||||||
Valuation Ratios (Price Multiples) | ||||||||||||||||||
Price to sales (P/S) |
Based on: 10-K (reporting date: 2022-12-31).
If the company price multiple is lower then the price multiple of benchmark then company stock is relatively undervalued.
Otherwise, if the company price multiple is higher then the price multiple of benchmark then company stock is relatively overvalued.
Historical Valuation Ratios (Summary)
Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
---|---|---|---|---|---|---|
Price to earnings (P/E) | ||||||
Price to operating profit (P/OP) | ||||||
Price to sales (P/S) | ||||||
Price to book value (P/BV) |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
- Price to Sales (P/S) Ratio
- The Price to Sales (P/S) ratio displays a generally increasing trend over the observed periods. Starting at 10.47 in 2018, it rose sharply to 32.88 in 2019, followed by a decline to 23.86 in 2020. However, from 2020 onwards, the ratio increased again, reaching 42.19 in 2021 and further advancing slightly to 43.37 in 2022. This indicates a growing market valuation relative to sales over time, with some volatility occurring in the middle years.
- Price to Book Value (P/BV) Ratio
- The Price to Book Value (P/BV) ratio shows fluctuations with incomplete data points across the periods. It was 12.72 in 2018, decreased to 11.75 in 2020, and then showed a slight increase to 12.19 in 2021. Data for 2019 and 2022 are missing, which limits the ability to observe a fully continuous trend. Overall, the ratio remains relatively stable within a narrow range around 12.
- Price to Earnings (P/E) and Price to Operating Profit (P/OP) Ratios
- No data is available for the Price to Earnings (P/E) and Price to Operating Profit (P/OP) ratios throughout the periods reviewed, preventing any analysis or identification of trends for these financial metrics.
Price to Earnings (P/E)
Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
---|---|---|---|---|---|---|
No. shares of common stock outstanding1 | ||||||
Selected Financial Data (US$) | ||||||
Net loss (in thousands) | ||||||
Earnings per share (EPS)2 | ||||||
Share price1, 3 | ||||||
Valuation Ratio | ||||||
P/E ratio4 | ||||||
Benchmarks | ||||||
P/E Ratio, Competitors5 | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
Vertex Pharmaceuticals Inc. | ||||||
P/E Ratio, Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | ||||||
P/E Ratio, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 Data adjusted for splits and stock dividends.
2 2022 Calculation
EPS = Net loss ÷ No. shares of common stock outstanding
= ÷ =
3 Closing price as at the filing date of Cytokinetics Inc. Annual Report.
4 2022 Calculation
P/E ratio = Share price ÷ EPS
= ÷ =
5 Click competitor name to see calculations.
The financial data over the five-year period reveals several notable trends and insights.
- Share Price
- The share price exhibits a strong upward trend, increasing from $6.01 at the end of 2018 to $43.11 by the end of 2022. This represents more than a sevenfold increase over the five-year span, with particularly sharp rises in 2021 and 2022, indicating growing market confidence or positive developments driving investor interest.
- Earnings Per Share (EPS)
- The EPS values consistently remain negative throughout the period, indicating that the company has reported net losses each year. Starting at -$1.94 in 2018, the EPS slightly deteriorated to -$2.05 in 2019 but improved marginally to -$1.79 in 2020. However, the losses deepened significantly in 2021 and 2022, falling to -$2.54 and then sharply to -$4.09. This worsening performance suggests increasing expenses, reduced profitability, or challenges in operational efficiency during the most recent years.
- Price-to-Earnings (P/E) Ratio
- The P/E ratio data is missing for all years, which is consistent with negative earnings per share. Since P/E ratios are generally not calculated or meaningful when earnings are negative, this absence reflects the company's continued unprofitability over the observed period.
Overall, despite the significant appreciation in the share price, the company has not achieved profitability in the assessed timeframe. The simultaneous increase in share price and worsening EPS suggests that investors may be valuing potential future growth or other qualitative factors rather than current earnings performance.
Price to Operating Profit (P/OP)
Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
---|---|---|---|---|---|---|
No. shares of common stock outstanding1 | ||||||
Selected Financial Data (US$) | ||||||
Operating loss (in thousands) | ||||||
Operating profit per share2 | ||||||
Share price1, 3 | ||||||
Valuation Ratio | ||||||
P/OP ratio4 | ||||||
Benchmarks | ||||||
P/OP Ratio, Competitors5 | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
Vertex Pharmaceuticals Inc. | ||||||
P/OP Ratio, Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | ||||||
P/OP Ratio, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 Data adjusted for splits and stock dividends.
2 2022 Calculation
Operating profit per share = Operating loss ÷ No. shares of common stock outstanding
= ÷ =
3 Closing price as at the filing date of Cytokinetics Inc. Annual Report.
4 2022 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= ÷ =
5 Click competitor name to see calculations.
- Share Price Trend
- Over the five-year period, the share price exhibited a consistent upward trend. Starting at $6.01 at the end of 2018, the share price more than doubled by the end of 2019 to $14.86, showing substantial investor confidence or positive market sentiment toward the company. The growth continued through 2020 and 2021, reaching $18.73 and $35.02 respectively, indicating sustained momentum. By the end of 2022, the share price had further increased to $43.11, nearly a sevenfold increase over the five years, reflecting a strong appreciation in market value.
- Operating Profit Per Share
- Operating profit per share remained negative throughout the period, indicating ongoing operating losses. The losses slightly deepened from -$1.62 in 2018 to -$1.66 in 2019, followed by a reduction in losses to -$1.32 in 2020, which may suggest temporary improvement or cost management. However, losses then worsened to -$2.20 in 2021 and further declined to -$3.41 in 2022. This trend points to increasing operational challenges or higher expenses impacting profitability despite the rising share price.
- Price to Operating Profit Ratio (P/OP)
- Data for the price to operating profit ratio (P/OP) was not provided, thus precluding any analysis on this metric.
Price to Sales (P/S)
Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
---|---|---|---|---|---|---|
No. shares of common stock outstanding1 | ||||||
Selected Financial Data (US$) | ||||||
Revenues (in thousands) | ||||||
Sales per share2 | ||||||
Share price1, 3 | ||||||
Valuation Ratio | ||||||
P/S ratio4 | ||||||
Benchmarks | ||||||
P/S Ratio, Competitors5 | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
Vertex Pharmaceuticals Inc. | ||||||
P/S Ratio, Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | ||||||
P/S Ratio, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 Data adjusted for splits and stock dividends.
2 2022 Calculation
Sales per share = Revenues ÷ No. shares of common stock outstanding
= ÷ =
3 Closing price as at the filing date of Cytokinetics Inc. Annual Report.
4 2022 Calculation
P/S ratio = Share price ÷ Sales per share
= ÷ =
5 Click competitor name to see calculations.
The financial data demonstrates a consistent upward trend in the share price of the company over the five-year period, with the share price increasing from $6.01 at the end of 2018 to $43.11 at the end of 2022. This represents a significant growth, indicating increasing investor confidence or improved market perception of the company.
Sales per share show variability but an overall positive trend. The value began at $0.57 in 2018, dipped to $0.45 in 2019, and then increased steadily each subsequent year, reaching $0.99 by the end of 2022. This suggests that the company has been able to grow its sales output relative to its share count, despite some short-term fluctuations.
The price-to-sales (P/S) ratio exhibits considerable fluctuation but generally trends upward, starting at 10.47 in 2018, sharply increasing to 32.88 in 2019, then decreasing to 23.86 in 2020 before climbing again to 42.19 in 2021 and slightly to 43.37 in 2022. The elevated and rising P/S ratio over time indicates that the market's valuation of the company relative to its sales has increased substantially, which could reflect expectations of future growth or profitability beyond current sales figures.
- Share Price Trends
- Steady and significant increase from $6.01 to $43.11 over five years.
- Sales Per Share Trends
- Initial decline from 2018 to 2019, followed by consistent growth through 2022, ending nearly double the 2019 low.
- Price-to-Sales Ratio Trends
- Large fluctuations with an overall rising trajectory, reflecting increasing market valuation relative to sales.
In summary, the data indicates strong market performance and growing sales per share, accompanied by a heightened valuation as expressed through the P/S ratio. The combination of rising share price and increasing P/S ratio suggests heightened investor expectations, which could imply anticipated operational improvements or market positioning advantages. However, the volatility in sales per share and the P/S ratio also suggest some variability in sales growth and valuation assessment over the years.
Price to Book Value (P/BV)
Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
---|---|---|---|---|---|---|
No. shares of common stock outstanding1 | ||||||
Selected Financial Data (US$) | ||||||
Stockholders’ equity (deficit) (in thousands) | ||||||
Book value per share (BVPS)2 | ||||||
Share price1, 3 | ||||||
Valuation Ratio | ||||||
P/BV ratio4 | ||||||
Benchmarks | ||||||
P/BV Ratio, Competitors5 | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
Vertex Pharmaceuticals Inc. | ||||||
P/BV Ratio, Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | ||||||
P/BV Ratio, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 Data adjusted for splits and stock dividends.
2 2022 Calculation
BVPS = Stockholders’ equity (deficit) ÷ No. shares of common stock outstanding
= ÷ =
3 Closing price as at the filing date of Cytokinetics Inc. Annual Report.
4 2022 Calculation
P/BV ratio = Share price ÷ BVPS
= ÷ =
5 Click competitor name to see calculations.
- Share Price
- The share price exhibited a strong upward trend over the five-year period, rising from $6.01 at the end of 2018 to $43.11 by the end of 2022. Notably, there was a significant increase between 2020 and 2021, where the price nearly doubled from $18.73 to $35.02, and continued to increase in 2022, though at a slower pace.
- Book Value Per Share (BVPS)
- The book value per share showed considerable volatility throughout the period. It started at $0.47 in 2018, declined to a negative value of -$0.18 in 2019, then rebounded sharply to $1.59 in 2020 and further increased to $2.87 in 2021. However, in 2022, BVPS dropped significantly to -$1.13, indicating a reversal to negative shareholders' equity.
- Price-to-Book Value (P/BV) Ratio
- The price-to-book value ratio was relatively high, with values around 12 in 2018, 2020, and 2021, suggesting the market valued the company's shares significantly above its book value during these years. Data for 2019 and 2022 are missing, which limits the ability to fully assess trends in this ratio. The high ratios in the available years reflect a market premium possibly driven by growth expectations or intangible assets not captured in book value.
- Overall Insights
- The share price growth contrasted with the fluctuations and eventual decline in book value per share by the end of 2022. This divergence suggests that market valuation increased independently of the company’s accounting net asset value, potentially reflecting investor optimism or expectations not grounded in book equity. The negative book value at the end of 2022 poses a concern regarding the company's financial stability, while the elevated price-to-book ratios highlight a market willing to pay a high premium relative to the recorded net asset value.